AB0879 Interim analysis of baseline characteristics and 12-week outcomes for a subset of patients with moderate-to-severe plaque psoriasis and psoriatic arthritis from the Psoriasis Study of Health Outcomes [PDF]
L. E. Kristensen +9 more
openalex +1 more source
Biologic treatments for psoriasis have different anatomical specificities in residual PASI
Summary Background and objectives Improved understanding of the immunopathogenesis of psoriasis has led to the development of effective targeted therapies, but patients who respond to treatment without total skin clearance have residual disease. The aim of this study was to demonstrate the existence of specific residual disease (or residual PASI ...
Martina Burlando +8 more
wiley +1 more source
Psoriatic Arthritis and Sarcopenia: A CrossSectional Ultrasonographic Study. [PDF]
Doğan Tosun GC +4 more
europepmc +1 more source
Decoding the Prescriber: Dermatology Versus Rheumatology Approaches
Australasian Journal of Dermatology, EarlyView.
Nicole Kah Mun Yoong +2 more
wiley +1 more source
A matter arising: When should inflammatory and autoimmune rheumatic diseases be considered ‘early’?
Timely recognition of inflammatory and autoimmune rheumatic diseases (IARDs) is important to optimize the early diagnosis with tailored interventions and possible prevention of irreversible organ damage. This narrative review provides an update by summarizing the advances in identifying the early stages of rheumatoid arthritis, systemic sclerosis and ...
Elvis Hysa +7 more
wiley +1 more source
Validation of Turkish psoriatic arthritis screening tool for psoriatic arthritis: A cross-sectional comparative study. [PDF]
Başar Kilic Ş +3 more
europepmc +1 more source
What Is the Diagnostic Capacity of Existing Severity Scoring Tools for Nail Psoriasis?
ABSTRACT Background It is challenging to distinguish nail psoriasis (NP) from nonspecific nail changes, contributing to heterogeneity in clinical trials. Existing scoring tools for NP are currently used to assess severity after diagnosis is established.
Evi C. C. Rikken +5 more
wiley +1 more source
Super‐response to Guselkumab. ABSTRACT Background Guselkumab, a selective interleukin (IL)‐23 inhibitor, is approved for the treatment of moderate‐to‐severe plaque psoriasis. While randomized clinical trials have introduced the concept of “super‐responders” (SRe)—patients achieving complete skin clearance (Psoriasis Area and Severity Index [PASI] 100 ...
Martina Kojanova +76 more
wiley +1 more source
Clinical and Ultrasound Characteristics of a Difficult-to-Treat Psoriatic Arthritis Population. [PDF]
Novell G +11 more
europepmc +1 more source

